-
Jan 21, 2025 | 
nature.com | Sina Gholami |Theodore Leng
AbstractVision impairment affects nearly 2.2 billion people globally, and nearly half of these cases could be prevented with early diagnosis and intervention—underscoring the urgent need for reliable and scalable detection methods for conditions like diabetic retinopathy and age-related macular degeneration.
-
Mar 1, 2024 | 
journals.healio.com | Brian Chhoy |Karen M. Wai |Theodore Leng
Request Username Can't sign in? Forgot your username?
-
Feb 27, 2024 | 
retina-specialist.com | Lucie Guo |Theodore Leng
Take-home pointsAnti-VEGF medications have been highly effective in clinical trials for improving vision in diabetic macular edema. In real-world settings, patients receive injections less frequently than in clinical trials. Real-world studies have reported smaller gains in vision than clinical trials. Real-world data highlight racial and socioeconomic disparities in the usage and outcome of anti-VEGF therapy.
-
Feb 27, 2024 | 
medrxiv.org | Rashadul Hasan Badhon |Jennifer Lim |Theodore Leng |Atalie Carina Thompson
The authors have declared no competing interest. This study was funded by NEI R15EY035804 (MNA) and UNC Charlotte Faculty Research Grant (MNA)I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
-
Jan 5, 2024 | 
journals.healio.com | Karen M. Wai |Theodore Leng |Brian Chhoy
IntroductionFibroblast growth factor receptors (FGFR) are a family of receptor tyrosine kinases involved in cell proliferation, cell migration, cell differentiation, and cell apoptosis. Overexpression of FGFR can cause abnormal cancer cell proliferation in cancers such as breast, glioblastoma, and hepatocellular cell carcinoma, and is thus the target of many chemotherapy agents. This class of drugs shows promise in targeted anti-cancer therapy.
-
Nov 22, 2023 | 
ophthalmologytimes.com | Theodore Leng
Ophthalmology is well positioned to help the FDA's Advancing Real-World Evidence Program unlock its fullest potential. Few, if any, other specialties or subspecialties provide the level of data quality required for these regulatory-level use cases. Data quality in this context is broadly objective.
-
Oct 24, 2023 | 
healio.com | Theodore Leng |Anthony DeFino |Christine Klimanskis
You've successfully added Ophthalmology: Retina/Vitreous to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective, Theodore Leng, MD, FACS,discusses the real-world use of faricimab for neovascular age-related macular degeneration.
-
Aug 10, 2023 | 
healio.com | Theodore Leng |Christine Klimanskis
Biography/Disclosures
Biography:
Theodore Leng, MD, MS, is a practicing retina specialist, associate professor of ophthalmology and director of clinical and translational research at the Byers Eye Institute at Stanford, Stanford University Medical School. He has a research background in image analysis, machine learning algorithms, and clinical trial design and execution.
Disclosures: Leng reports being a medical advisor for Verana Health.
-
Aug 1, 2023 | 
healio.com | Theodore Leng |Anthony DeFino |Christine Klimanskis
Source/Disclosures
Source:
Leng T. Early treatment patterns and outcomes in patients with neovascular age related macular degeneration initiating faricimab: The FARETINA-AMD study. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Disclosures:
Leng reports consulting for Roche/Genentech.
Source/Disclosures
Source:
Leng T.
-
Jul 27, 2023 | 
healio.com | Theodore Leng |Christine Klimanskis
Biography/Disclosures
Biography:
Theodore Leng, MD, MS, is a practicing retina specialist, associate professor of ophthalmology and director of clinical and translational research at the Byers Eye Institute at Stanford, Stanford University Medical School. He has a research background in image analysis, machine learning algorithms, and clinical trial design and execution.
Disclosures: Leng reports being a medical advisor for Verana Health.
